President & Chief Executive Officer, PDC*line Pharma
Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During my career I achieved together with my different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, Eric has raised as of now a total of more than €130 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is President and CEO of the biotechnology company PDC*line Pharma and board member of VitriCell and Essenscia (Bio.be). Eric is co-founder of four biotechnology called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric worked for 12 years in the Healthcare and Life Sciences Practice of Arthur D. Little. Eric holds two master degrees in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.
Stevenage Bioscience Catalyst30 November 2023